[The anti-platelet aggregation drugs: new approaches based on snake venom polypeptides].
Marrakchi
N
N
Laboratoire Venins et Toxines, Institut Pasteur de Tunis.
Guermazi
S
S
El Ayeb
M
M
D000595:Amino Acid Sequence; D000818:Animals; D001241:Aspirin / Q000627:therapeutic use; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D006801:Humans; D013058:Mass Spectrometry; D008969:Molecular Sequence Data; D010455:Peptides / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use*; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D010974:Platelet Aggregation / Q000187:drug effects / Q000502:physiology; D010975:Platelet Aggregation Inhibitors / Q000737:chemistry / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D012910:Snake Venoms / Q000737:chemistry*; D013927:Thrombosis / Q000188:drug therapy* / Q000517:prevention & control; D013988:Ticlopidine / Q000627:therapeutic use; D014757:Viper Venoms / Q000737:chemistry
D016861:Cyclooxygenase Inhibitors; D010455:Peptides; D010726:Phosphodiesterase Inhibitors; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D012910:Snake Venoms; D014757:Viper Venoms; C101100:lebetin 1; C101101:lebetin 2; C067623:kistrin; D013988:Ticlopidine; D001241:Aspirin